Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE vs DISOPYRAMIDE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; quinidine is a CYP2D6 inhibitor that increases dextromethorphan bioavailability.
Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.
Pseudobulbar affect (PBA) - FDA approved
Treatment of life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Suppression of symptomatic atrial fibrillation/flutter
One capsule (dextromethorphan 20 mg/quinidine 10 mg) orally once daily, with a maximum dose of two capsules per day.
100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.
Dextromethorphan: 2-4 hours (extensive metabolizers); quinidine: 6-8 hours (inhibits CYP2D6, prolonging dextromethorphan half-life in poor metabolizers to >20 hours)
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged to 15-25 hours in renal impairment (creatinine clearance <40 m L/min), requiring dose adjustment.
Dextromethorphan is primarily metabolized by CYP2D6 to dextrorphan; quinidine is a potent CYP2D6 inhibitor at low doses.
Primarily hepatic metabolism via CYP3A4; approximately 40-60% excreted unchanged in urine.
Renal: quinidine 15-25% unchanged, dextromethorphan <1% unchanged; biliary/fecal: quinidine metabolites ~5%, dextromethorphan metabolites ~60-80% as dextrorphan conjugates
Renal excretion of unchanged drug accounts for 40-60% of elimination; hepatic metabolism (N-dealkylation) accounts for 20-30%; approximately 10-15% excreted in feces via biliary elimination.
Dextromethorphan: ~60-70% (albumin); quinidine: 80-90% (albumin, alpha-1-acid glycoprotein)
50-65% bound to plasma proteins (primarily to alpha-1-acid glycoprotein, with lower affinity to albumin).
Dextromethorphan: 5-6 L/kg; quinidine: 2-3 L/kg
0.8-1.4 L/kg (extensive tissue distribution; higher in myocardial tissue than plasma).
Oral: dextromethorphan ~11% (extensive first-pass metabolism; increased to >50% when coadministered with quinidine); quinidine ~70-80%
Oral: 80-90% (immediate-release); 60-80% (sustained-release due to incomplete absorption).
For creatinine clearance (Cr Cl) 30–59 m L/min: reduce dose to one capsule once daily. For Cr Cl <30 m L/min: not recommended.
GFR 30-50 m L/min: 100 mg every 8-12 hours; GFR 15-29 m L/min: 100 mg every 12-24 hours; GFR <15 m L/min or dialysis: 100 mg every 24 hours or 50 mg every 12 hours.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: not recommended (quinidine is extensively metabolized by the liver).
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use or reduce by 75%.
Safety and efficacy in pediatric patients have not been established; not recommended for use in children.
Children <1 year: 10-30 mg/kg/day divided every 6 hours; 1-4 years: 10-30 mg/kg/day divided every 6 hours; 4-12 years: 10-30 mg/kg/day divided every 6 hours; adolescents: same as adult dosing up to 400 mg/day.
Initiate at one capsule once daily; titrate cautiously. Monitor for QT prolongation and anticholinergic effects. Lower doses may be required due to age-related renal and hepatic decline.
Start at low end of dosing range (100 mg every 6 hours) due to decreased renal function and increased sensitivity; monitor QTc interval and anticholinergic effects.
None.
Disopyramide has negative inotropic effects and may precipitate or exacerbate heart failure. Use with caution in patients with pre-existing heart failure or significant left ventricular dysfunction.
CNS depression: may cause dizziness, somnolence; avoid alcohol.,Cardiotoxicity: quinidine may cause QT prolongation; monitor ECG.,Serotonin syndrome: risk with concurrent serotonergic drugs.,Hepatic impairment: use with caution.,Renal impairment: not recommended in severe renal disease.
May worsen or precipitate heart failure due to negative inotropy,Risk of proarrhythmia (e.g., torsades de pointes) especially with hypokalemia or bradycardia,Anticholinergic effects: urinary retention, dry mouth, blurred vision, constipation,May cause hypoglycemia in rare cases,Dose adjustment required in renal or hepatic impairment
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days.,Concomitant use with other drugs that prolong QT interval.,Known hypersensitivity to dextromethorphan or quinidine.,Complete atrioventricular block without pacemaker.,History of drug-induced torsades de pointes.
Cardiogenic shock,Pre-existing second- or third-degree AV block (without pacemaker),Known hypersensitivity to disopyramide,Severe heart failure or left ventricular dysfunction
Avoid grapefruit and grapefruit juice as they may increase plasma levels of quinidine, raising risk of toxicity including QT prolongation. Avoid excessive alcohol consumption as it may exacerbate CNS depression.
Avoid grapefruit juice as it may increase disopyramide concentrations. Limit caffeine intake as it may worsen arrhythmias. Avoid high-fat meals as they may reduce absorption.
First trimester: Limited human data; animal studies show quinidine sulfate associated with increased risk of fetal malformations at high doses. Second/third trimester: Dextromethorphan hydrobromide not associated with major malformations; quinidine sulfate may cause fetal bradycardia and hypoglycemia due to quinidine's antiarrhythmic effects. Overall: No adequate human studies; use only if benefit outweighs risk.
Disopyramide crosses the placenta. First trimester: No well-controlled studies; potential for adverse effects based on animal data. Second and third trimesters: May stimulate uterine contractions, potentially causing preterm labor; reports of neonatal hypoglycemia and respiratory depression. Not recommended during pregnancy unless benefit outweighs risk.
Dextromethorphan: Likely excreted in breast milk in low amounts; M/P ratio not reported. Quinidine: Excreted in breast milk; M/P ratio approximately 0.71. Potential for infant quinidine toxicity (cinchonism, arrhythmias). Avoid breastfeeding during maternal quinidine therapy.
Disopyramide is excreted into breast milk with milk-to-plasma ratio of approximately 0.9. Infant exposure estimated at 2–6% of maternal weight-adjusted dose. Monitor infant for bradycardia, hypoglycemia, and apnea. Weigh benefits against potential risks.
No specific pharmacokinetic studies in pregnancy; increased renal clearance of dextromethorphan in third trimester may lower exposure. For quinidine, plasma protein binding decreases in pregnancy, potentially increasing free drug fraction. Dose adjustment not recommended due to lack of data; titrate based on clinical response and toxicity monitoring.
Dose may require adjustment due to pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance, altered protein binding). Monitor serum disopyramide levels and therapeutic response; consider lower starting doses and titrate to effect.
Monitor for QT prolongation with baseline and periodic ECG, especially in patients with hypokalemia, hypomagnesemia, or bradycardia. Avoid use with CYP3A4 inhibitors (e.g., ketoconazole) or CYP2D6 inhibitors (e.g., paroxetine) due to quinidine metabolism. Quinidine is a potent CYP2D6 inhibitor; caution with concurrent CYP2D6 substrates like tricyclic antidepressants. Onset of pseudobulbar affect improvement may take weeks; titrate dose gradually.
Disopyramide is a class IA antiarrhythmic with significant negative inotropic and anticholinergic effects. Avoid in patients with heart failure, cardiogenic shock, or glaucoma. Dose adjustment required in renal impairment. Monitor QRS and QT intervals; proarrhythmia risk. May cause hypoglycemia in elderly or diabetic patients. Therapeutic drug monitoring recommended (target 2-5 mcg/m L).
Take this medication exactly as prescribed; do not double doses if missed.,Avoid grapefruit juice as it may increase side effects.,Report any signs of irregular heartbeat (palpitations, dizziness, fainting) or allergic reactions (rash, difficulty breathing).,May cause dizziness or blurred vision; avoid driving until you know how it affects you.,Do not stop abruptly; dose reduction should be gradual under medical supervision.,Inform all healthcare providers about this medication, especially before any surgery or dental procedure.
Take exactly as prescribed; do not skip doses or double up.,Do not take with grapefruit juice.,Avoid alcohol and other CNS depressants.,Report symptoms of heart failure (shortness of breath, swelling) or arrhythmia (palpitations, syncope).,May cause dry mouth, blurred vision, urinary retention; use caution driving.,Monitor blood sugar if diabetic.,Do not stop abruptly without consulting your doctor.
"The coadministration of nisoldipine, a calcium channel blocker, with quinidine, a Class Ia antiarrhythmic, results in a significant reduction in quinidine serum concentrations. This interaction is primarily due to nisoldipine-induced enhancement of hepatic quinidine metabolism via cytochrome P450 3A4 induction, leading to subtherapeutic quinidine levels and potential loss of antiarrhythmic efficacy. Clinically, patients may experience breakthrough arrhythmias or inadequate suppression of atrial or ventricular arrhythmias."
"Scopolamine, an anticholinergic agent, and Quinidine, a Vaughan-Williams Class Ia antiarrhythmic with anticholinergic properties, exhibit additive anticholinergic effects when coadministered. This synergy can lead to enhanced peripheral and central anticholinergic adverse effects, including dry mouth, blurred vision, urinary retention, constipation, tachycardia, confusion, and cognitive impairment, particularly in elderly patients. The risk is significant as both drugs block muscarinic acetylcholine receptors, potentially precipitating anticholinergic toxicity."
"Vernakalant, a multi-ion channel blocker primarily used for atrial fibrillation conversion, can inhibit cytochrome P450 (CYP) 3A4, the major enzyme responsible for the metabolism of quinidine. This results in elevated plasma concentrations of quinidine, increasing the risk of quinidine-related cardiotoxicity, including QTc prolongation, torsade de pointes, and other ventricular arrhythmias. The interaction may also potentiate vagolytic effects and negative inotropy, leading to hemodynamic compromise."
"Disopyramide, a class Ia antiarrhythmic agent, prolongs the QT interval by inhibiting cardiac potassium channels, thereby increasing the risk of torsades de pointes. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), also has dose-dependent QT-prolonging effects, primarily through hERG channel blockade. Concomitant use synergistically lengthens the QT interval, predisposing patients to potentially fatal ventricular arrhythmias, especially in those with pre-existing risk factors such as hypokalemia, bradycardia, or genetic long QT syndrome."
"Disopyramide, a class Ia antiarrhythmic agent, prolongs ventricular repolarization by blocking cardiac sodium and potassium channels. Ezogabine, a potassium channel opener, also has dose-dependent effects on cardiac repolarization. Coadministration may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Disopyramide, a class Ia antiarrhythmic agent, may potentiate the hypoglycemic effects of cinoxacin, a quinolone antibiotic, by enhancing insulin secretion and increasing peripheral glucose uptake. This interaction can lead to clinically significant hypoglycemia, particularly in patients with diabetes mellitus or those concurrently using other hypoglycemic agents. Patients may experience symptoms such as diaphoresis, palpitations, confusion, or loss of consciousness if blood glucose levels drop precipitously."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE vs DISOPYRAMIDE PHOSPHATE, answered by our medical review team.
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is a Antiarrhythmic (Class Ia) that works by Dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; quinidine is a CYP2D6 inhibitor that increases dextromethorphan bioavailability.. DISOPYRAMIDE PHOSPHATE is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE and DISOPYRAMIDE PHOSPHATE depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is: One capsule (dextromethorphan 20 mg/quinidine 10 mg) orally once daily, with a maximum dose of two capsules per day.. The standard adult dose of DISOPYRAMIDE PHOSPHATE is: 100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE and DISOPYRAMIDE PHOSPHATE. Disopyramide and Quinidine are both Vaughan Williams Class Ia antiarrhythmic agents that prolong the QT interval by blocking cardiac potassium channels, primarily IKr. Concurrent use synergistically increases the risk of torsades de pointes, a potentially fatal ventricular arrhythmia, especially in patients with predisposing factors such as hypokalemia, bradycardia, or preexisting QT prolongation. Clinically, this combination may lead to syncope, sudden cardiac death, or require urgent defibrillation. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is classified as Category A/B. First trimester: Limited human data; animal studies show quinidine sulfate associated with increased risk of fetal malformations at high doses. Second/third trimester: Dextromethor. DISOPYRAMIDE PHOSPHATE is classified as Category D/X. Disopyramide crosses the placenta. First trimester: No well-controlled studies; potential for adverse effects based on animal data. Second and third trimesters: May stimulate uteri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.